Endocrine Abstracts

Introduction

Pituitary diseases result in clinical consequences and increased mortality due to tumors mass effects and also due to pituitary hypersecretion and insufficiency. Pituitary tumors registry enables identification of diagnostic and prognostic markers. The registry improves long-term clinical outcomes, pituitary diseases care and management.

The aim of this study

Our registry study is designed to create a unified database of pituitary disease patients in Latvia for the first time.

Materials and methods

We collected 3 yrs data from pnts medical records with pituitary diseases and tumors from Clinical University Hospital Outpatient Clinic and from 4 Outpatients Clinics in Riga and in Jelgava, which were the workplaces of both authors. Prospective cohort analysis was performed based on demographic data, MRI and lab. data, data on medications, doses, and regimens, information on co-morbidities and concomitant medications. We collected pnts with pituitary diseases and tumors: prolactinomas, CNFA, acromegalies, empty sella syndr., Cushing’s disease (CD), Ratke’s pocket cysts, meningiomas, craniopharyngioma, pituitary aplasia or hypoplasia, TSH-omas, germinoma, glioma, chondrosarcoma, pericytoma.

Results

355 pnts (71.7% women) with pituitary diseases were registered from July 2016 to July 2019. The mean age was 43.4 yrs (range 18–83 yrs). Prolactinomas were the most common adenomas (40.8%), followed by CNFA (28.5%), acromegaly (16.1%) and than empty sella syndrome (5.1%), CD (2.3%), Ratchet pocket cysts (2.3%), meningiomas (1.4%), craniopharyngiomas (1.1%), pituitary aplasia and hypoplasia (0.8%), TSH-omas (0.6%), germinoma (0.3%), glioma (0.3%), chondrosarcoma (0.3%), pericitoma (0.3%). Patients in this cohort most often received drug therapy with any medication alone or in combination (octreotide LAR, lanreotide, bromocriptine, cabergoline, pegvisomant) in 50.5% of cases. The majority of 94.7% of patients (n = 336) had 1 or more co-morbidities. The most common group of comorbidities was the thyroid disease group (n = 289). The next - the cardiovascular diseases group (n = 273), vitamin D deficiency 76.2% (n = 256), dyslipidaemia 59.2% (n = 199), various types of diabetes mellitus/carbohydrate metabolism disorders 36.3% (n = 122), non-alcoholic steatohepatosis (NASH) 19.3% (n = 65), osteoarthritis 17.9% (n = 60), primary/secondary osteoporosis/osteopenia 7.1% (n = 24), gallstone disease 10.4% (n = 35), etc. The majority of pnts (81.7%) were treated with 1 or more concomitant medications.

Conclusions

As a result of this study, a unified database of pnts with pituitary diseases has been created, and data on 14 different pituitary diseases has been collected in register, which allows analyzing the population characteristics of the pituitary diseases, the applied treatment schemes for the treatment of pituitary diseases; types of neurosurgery, medications data.